Myocardial oxidative stress contributes to transgenic β 2- adrenoceptor activation-induced cardiomyopathy and heart failure

British Journal of Pharmacology

Volumn 162, Issue 5, 2011, Pages 1012-1028

  Xu, Q ^a   Dalic, A ^a   Fang, L ^a   Kiriazis, H ^a   Ritchie, R H ^a,b   Sim, K ^a   Gao, X M ^a,b   Drummond, G ^b   Sarwar, M ^b   Zhang, Y Y ^c   Dart, A M ^b,d   Du, X J ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

^d ALFRED HOSPITAL   (Australia)

Author keywords

adrenoceptor; cardiomyopathy; fibrosis; heart failure; inflammation; NADPH oxidase; p38 MAPK; reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; APOCYNIN; BETA 2 ADRENERGIC RECEPTOR; COLLAGEN; CYTOKINE; DIPHENYLIODONIUM SALT; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART CONTRACTION; HEART DILATATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE FAILURE; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; CARDIOMYOPATHIES; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; HEART FAILURE; HSP27 HEAT-SHOCK PROTEINS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; NADPH OXIDASE; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, ADRENERGIC, BETA-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 79551501701     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01043.x     Document Type: Article

References (50)

1. 1-AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther 325: 491-499.
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Anrather J, Racchumi G, Iadecola C, (2006). NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 281: 5657-5667.
4. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, et al. (2001). Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89: 997-1004.
5. Bristow MR, (2000). β-adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569.
6. 1-receptor down-regulation in heart failure. Circ Res 59: 297-309.
7. Brum PC, Kosek J, Patterson A, Bernstein D, Kobilka B, (2002). Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am J Physiol Heart Circ Physiol 283: H1838-H1845.
8. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, et al. (2003). Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93: 802-805.
9. 2- adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 65: 1595-1610.
10. Chen Y, Rajashree R, Liu Q, Hofmann P, (2003). Acute p38 MAPK activation decreases force development in ventricular myocytes. Am J Physiol Heart Circ Physiol 285: H2578-H2586.
11. Cohn JN, (1990). Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation 82: I59-I67.
12. 2-adrenergic receptor. J Biol Chem 283: 5669-5676.
13. 2-adrenergic receptors in the heart. Cardiovasc Res 48: 448-454.
14. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059-7064.
15. Feldman DS, Elton TS, Sun B, Martin MM, Ziolo MT, (2008). Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med 5: 208-218.
16. 2-adrenergic receptor overexpression. Endocrinology 144: 4097-4105.
17. 2-adrenergic receptors. J Biol Chem 283: 29028-29036.
18. Hardt SE, Geng YJ, Montagne O, Asai K, Hong C, Yang GP, et al. (2002). Accelerated cardiomyopathy in mice with overexpression of cardiac Gsα and a missense mutation in the α-myosin heavy chain. Circulation 105: 614-620.
19. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, et al. (2009). NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 15: 1077-1081.
20. 2-adrenoceptor agonists. Am Heart J 142: E11.
21. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. (2005). ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112: e154-e235.
22. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD, (1995). Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26: 1257-1263.
23. 2-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis. Br J Pharmacol 153: 684-692.
24. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S, (2003). Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278: 22546-22554.
25. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM, et al. (2006). Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72: 112-123.
26. Li M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J, et al. (2005). p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111: 2494-2502.
27. Liao P, Wang SQ, Wang S, Zheng M, Zhang SJ, Cheng H, et al. (2002). p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 90: 190-196.
28. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101: 1707-1714.
29. 2-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes. Mol Cell Biol 29: 675-686.
30. 2-adrenergic receptor. Science 264: 582-586.
31. 2-adrenoceptor agonists for the management of muscle wasting. Br J Pharmacol 147: 583-586.
32. 2 -adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch Pharmacol 375: 11-28.
33. 2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327: 1653-1657.
34. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA, (2008). Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3: 1422-1434.
35. 1-adrenergic receptor. J Clin Invest 117: 1335-1343.
36. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7-13.
37. Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, et al. (2003). β-Adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92: 136-138.
38. Ren J, Zhang S, Kovacs A, Wang Y, Muslin AJ, (2005). Role of p38α MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol 38: 617-623.
39. Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, Favaloro JM, et al. (2007). The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 42: 1119-1128.
40. 2+-ATPase protein and activity. Am J Physiol Heart Circ Physiol 294: H2587-H2595.
41. 2-Adrenergic receptor overexpression driven by α-MHC promoter is downregulated in hypertrophied and failing myocardium. Cardiovasc Res 47: 133-141.
42. 2B adenosine receptor gene: the role of NAD(P)H oxidase 4. Biochem Biophys Res Commun 375: 292-296.
43. Takimoto E, Kass DA, (2007). Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241-248.
44. 1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem 284: 20375-20386.
45. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hasegawa G, Naito M, et al. (2000). Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 130: 1489-1495.
46. Xu Q, Lekgabe ED, Gao XM, Ming Z, Tregear GW, Dart AM, et al. (2008). Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis. Endocrinology 149: 476-482.
47. Yin F, Li P, Zheng M, Chen L, Xu Q, Chen K, et al. (2003). Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart. J Biol Chem 278: 21070-21075.
48. 2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J Mol Cell Cardiol 40: 384-393.
49. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98: 1607-1612.
50. 2+/ calmodulin kinase II. J Clin Invest 111: 617-625.